TISIDB

Summary
Symbol	OLIG2
Name	oligodendrocyte lineage transcription factor 2
Aliases	RACK17; OLIGO2; bHLHe19; oligodendrocyte-specific bHLH transcription factor 2; protein kinase C binding prot ......
Chromosomal Location	21q22.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Cytoplasm Note=The NLS contained in the bHLH domain could be masked in the native form and translocation to the nucleus could be mediated by interaction either with class E bHLH partner protein or with NKX2-2.
Domain	PF00010 Helix-loop-helix DNA-binding domain
Function	Required for oligodendrocyte and motor neuron specification in the spinal cord, as well as for the development of somatic motor neurons in the hindbrain. Cooperates with OLIG1 to establish the pMN domain of the embryonic neural tube. Antagonist of V2 interneuron and of NKX2-2-induced V3 interneuron development (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0001708 cell fate specification GO:0007272 ensheathment of neurons GO:0008366 axon ensheathment GO:0010001 glial cell differentiation GO:0010720 positive regulation of cell development GO:0010721 negative regulation of cell development GO:0014013 regulation of gliogenesis GO:0014015 positive regulation of gliogenesis GO:0021510 spinal cord development GO:0021515 cell differentiation in spinal cord GO:0021517 ventral spinal cord development GO:0021522 spinal cord motor neuron differentiation GO:0021529 spinal cord oligodendrocyte cell differentiation GO:0021530 spinal cord oligodendrocyte cell fate specification GO:0021536 diencephalon development GO:0021778 oligodendrocyte cell fate specification GO:0021779 oligodendrocyte cell fate commitment GO:0021780 glial cell fate specification GO:0021781 glial cell fate commitment GO:0021794 thalamus development GO:0021953 central nervous system neuron differentiation GO:0030900 forebrain development GO:0042063 gliogenesis GO:0042552 myelination GO:0045165 cell fate commitment GO:0045665 negative regulation of neuron differentiation GO:0045685 regulation of glial cell differentiation GO:0045687 positive regulation of glial cell differentiation GO:0048663 neuron fate commitment GO:0048709 oligodendrocyte differentiation GO:0048713 regulation of oligodendrocyte differentiation GO:0048714 positive regulation of oligodendrocyte differentiation GO:0050768 negative regulation of neurogenesis GO:0050769 positive regulation of neurogenesis GO:0051961 negative regulation of nervous system development GO:0051962 positive regulation of nervous system development
Molecular Function	GO:0003705 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding GO:0071837 HMG box domain binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	OLIG2
Name	oligodendrocyte lineage transcription factor 2
Aliases	RACK17; OLIGO2; bHLHe19; oligodendrocyte-specific bHLH transcription factor 2; protein kinase C binding prot ......
Chromosomal Location	21q22.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between OLIG2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	OLIG2
Name	oligodendrocyte lineage transcription factor 2
Aliases	RACK17; OLIGO2; bHLHe19; oligodendrocyte-specific bHLH transcription factor 2; protein kinase C binding prot ......
Chromosomal Location	21q22.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of OLIG2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	OLIG2
Name	oligodendrocyte lineage transcription factor 2
Aliases	RACK17; OLIGO2; bHLHe19; oligodendrocyte-specific bHLH transcription factor 2; protein kinase C binding prot ......
Chromosomal Location	21q22.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of OLIG2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	1.585	0.0152
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	1.042	0.359
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	1.985	0.03
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.254	0.765
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.237	0.852
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.872	0.548
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.237	0.801
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.901	0.495
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.9	0.585
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0	1
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0	1
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.184	0.155

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of OLIG2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	OLIG2
Name	oligodendrocyte lineage transcription factor 2
Aliases	RACK17; OLIGO2; bHLHe19; oligodendrocyte-specific bHLH transcription factor 2; protein kinase C binding prot ......
Chromosomal Location	21q22.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of OLIG2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	OLIG2
Name	oligodendrocyte lineage transcription factor 2
Aliases	RACK17; OLIGO2; bHLHe19; oligodendrocyte-specific bHLH transcription factor 2; protein kinase C binding prot ......
Chromosomal Location	21q22.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of OLIG2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by OLIG2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	OLIG2
Name	oligodendrocyte lineage transcription factor 2
Aliases	RACK17; OLIGO2; bHLHe19; oligodendrocyte-specific bHLH transcription factor 2; protein kinase C binding prot ......
Chromosomal Location	21q22.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of OLIG2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	OLIG2
Name	oligodendrocyte lineage transcription factor 2
Aliases	RACK17; OLIGO2; bHLHe19; oligodendrocyte-specific bHLH transcription factor 2; protein kinase C binding prot ......
Chromosomal Location	21q22.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of OLIG2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	OLIG2
Name	oligodendrocyte lineage transcription factor 2
Aliases	RACK17; OLIGO2; bHLHe19; oligodendrocyte-specific bHLH transcription factor 2; protein kinase C binding prot ......
Chromosomal Location	21q22.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between OLIG2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	OLIG2
Name	oligodendrocyte lineage transcription factor 2
Aliases	RACK17; OLIGO2; bHLHe19; oligodendrocyte-specific bHLH transcription factor 2; protein kinase C binding prot ......
Chromosomal Location	21q22.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting OLIG2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse OLIG2